Minute Insight: Bioventus Completes CartiHeal Acquisition Following Agili-C Approval
Bioventus exercised a “call option” to acquire CartiHeal for about $315m, plus up to $135m in milestones. The US FDA recently approved CartiHeal’s Agili-C implant to treat knee joint surface lesions.
You may also be interested in...
At the live AAOS conference, exhibitors, including major orthopedics players, demoed digital innovations, software-enabled technologies, robotics and smart implants that are expected to create efficiencies in the surgical continuum and provide data to improve outcomes.
The Canadian robotic surgery company is still working toward an FDA approval for its Enos single-access robotic surgery system, but is laying off 40 people in its Chapel Hill, NC, offices to save money.
Using artificial intelligence and coronary computed tomography angiography Cleerly is trying to shift cardiology's focus from symptoms-based interventions to prevention and treatment of the underlying vascular disease.